This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca Voelker
JAMA contributor

JAMA. 1998;280:315.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Physicians treating patients with head and neck cancer may have new clinical options for predicting recurrences and staging treatment.

Researchers at the University of Pittsburgh School of Medicine report that levels of epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor (TGF-), can predict clinical outcomes as accurately as the traditional method of cervical lymph node dissection. Their finding is based on examinations of tumor tissue taken from 91 patients with head and neck cancer, which they compared with previous studies of patients without the disease. The research team used monoclonal antibodies and computerized image analysis to measure levels of EGFR and TGF-.

In their report, published June 3 in the Journal of the National Cancer Institute, the researchers said patients with head and neck cancer had elevated levels of the proteins in the tumor tissue, while patients without the disease had low levels. . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?